Metraipolis › archive › dc_f53e61325636

Sclerostin small-molecule inhibitors promote osteogenesis by activating canonical Wnt and BMP pathways — Europe PMC PMID:37560905

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/37560905
DOI
10.7554/elife.63402
License (as archived)
CC0-1.0
Archived
2026-10-07T12:29:15.569Z
SHA-256 of the archived text
7c2fcfc01cbe33d49713c4339b2be84ffe3083dcdd29beb815415d6c7167b850
Stable URL of this page
https://metraipolis.com/documento/dc_f53e61325636

How to cite

Sclerostin small-molecule inhibitors promote osteogenesis by activating canonical Wnt and BMP pathways — Europe PMC PMID:37560905 — Europe PMC (en), https://europepmc.org/article/MED/37560905 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f53e61325636 (Metraipolis archive dc_f53e61325636, sha256 7c2fcfc01cbe33d49713c4339b2be84ffe3083dcdd29beb815415d6c7167b850)
BibTeX
@misc{dcf53e61325636,
  title = {Sclerostin small-molecule inhibitors promote osteogenesis by activating canonical Wnt and BMP pathways — Europe PMC PMID:37560905},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/37560905},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f53e61325636; sha256 7c2fcfc01cbe33d49713c4339b2be84ffe3083dcdd29beb815415d6c7167b850},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37560905. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: The clinical healing environment after a posterior spinal arthrodesis surgery is one of the most clinically challenging bone-healing environments across all orthopedic interventions due to the absence of a contained space and the need to form de novo bone. Our group has previously reported that sclerostin in expressed locally at high levels throughout a developing spinal fusion. However, the role of sclerostin in controlling bone fusion remains to be established. Methods: We computationally identified two FDA-approved drugs, as well as a single novel small-molecule drug, for their ability to disrupt the interaction between sclerostin and its receptor, LRP5/6. The drugs were tested in several in vitro biochemical assays using murine MC3T3 and MSCs, assessing their ability to (1) enhance canonical Wnt signaling, (2) promote the accumulation of the active (non-phosphorylated) form of β-catenin, and (3) enhance the intensity and signaling duration of BMP signaling. These drugs were then tested subcutaneously in rats as standalone osteoinductive agents on plain collagen sponges. Finally, the top drug candidates (called VA1 and C07) were tested in a rabbit posterolateral spine fusion model for their ability to achieve a successful fusion at 6 wk. Results: We show that by controlling GSK3b phosphorylation our three small-molecule inhibitors (SMIs) simultaneously enhance canonical Wnt signaling and potentiate canonical BMP signaling intensity and duration. We also demonstrate that the SMIs produce dose-dependent ectopic mineralization in vivo in rats as well as significantly increase posterolateral spine fusion rates in rabbits in vivo, both as standalone osteogenic drugs and in combination with autologous iliac crest bone graft. Conclusions: Few if any osteogenic small molecules possess the osteoinductive potency of BMP itself - that is, the ability to form de novo ectopic bone as a standalone agent. Herein, we describe two such SMIs that have this unique ability and were shown to induce de novo bone in a stringent in vivo environment. These SMIs may have the potential to be used in novel, cost-effective bone graft substitutes for either achieving spinal fusion or in the healing of critical-sized fracture defects. Funding: This work was supported by a Veteran Affairs Career Development Award (IK2-BX003845).

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: eLife, 2023 (prima pubblicazione 2023-08-10).
Identificativi: PMID 37560905 · PMCID PMC10431921 · DOI 10.7554/elife.63402.
Parole chiave degli autori: Cell biology; Rat; Osteogenesis; Medicine; Small molecules; Spinal Fusion; Sclerostin; Canonical Wnt; Rabbit - Other Organism.
Descrittori MeSH principali: Spine; Osteogenesis.
Pagina: https://europepmc.org/article/MED/37560905 — https://doi.org/10.7554/elife.63402. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T12:01:43.254Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.